GlassScriptPhysician profile
Timothy S Gatz
NPI 1689780231
$2,160.29
in general payments reported to CMS, 2019-2025
19 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.63 · 2021: $12.41 · 2022: $16.09 · 2023: $662 · 2024: $1,276 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $216.81 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $203.20 | 2023-2025 | Breztri, Farxiga, Flumist Quadrivalent |
| Abbvie INC. | $187.50 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.03 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Glaxosmithkline, LLC. | $168.77 | 2020-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $167.08 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $154.21 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $116.00 | 2023-2024 | Gardasil 9, Gardasil, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $52.24 | 2023-2024 | |
| Phadia US INC. | $52.08 | 2023-2024 | Immunocap |
| Exact Sciences Corporation | $51.94 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $37.12 | 2023-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $32.77 | 2023 | Auvelity |
| Hologic Sales and Service, LLC | $27.55 | 2024 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.49 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $25.45 | 2025 | Eliquis |
| Idorsia Pharmaceuticals US INC | $22.39 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $21.27 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.